肺移植受者泊沙康唑片剂与口服混悬液对他克莫司和依维莫司谷浓度的影响
结果显示泊沙康唑片剂治疗时泊沙康唑谷浓度是混悬液的2.5倍,他克莫司和依维莫司按剂量调整的谷浓度分别升高3倍和3.5倍,他克莫司日剂量更低,提示片剂增加药物相互作用风险。
要点
- 泊沙康唑片剂谷浓度是混悬液的2.5倍。
- 泊沙康唑起始使他克莫司和依维莫司谷浓度分别升高3倍和3.5倍。
- 片剂治疗时他克莫司日剂量更低,需警惕不良反应。
核心结论
- 泊沙康唑片剂治疗达到更高泊沙康唑暴露,增强与他克莫司和依维莫司的药物相互作用,导致更高暴露,可能增加不良反应风险。
研究设计与样本
- 用液相色谱-串联质谱法常规治疗药物监测测定泊沙康唑血浆谷浓度(n=64)、他克莫司血谷浓度(n=299)和依维莫司血谷浓度(n=80)。
主要发现
- 泊沙康唑片剂治疗时泊沙康唑谷浓度(n=48)是混悬液治疗(n=16)的2.5倍,全体泊沙康唑患者P<.0001,转换患者P=.003。
- 泊沙康唑起始(无论剂型)使他克莫司和依维莫司按剂量调整的谷浓度分别升高3倍和3.5倍(两者P<.0001)。
- 泊沙康唑片剂治疗时他克莫司谷浓度/剂量(0.004±0.004 L-1 vs 0.009±0.006 L-1,P<.0001)高于混悬液,他克莫司日剂量更低(1.08±0.92 vs 2.32±1.62 mg d-1,P<.0001)。
- 泊沙康唑片剂治疗时依维莫司谷浓度/剂量高于混悬液,依维莫司剂量倾向于更低。
临床怎么用
- 肺移植受者使用泊沙康唑片剂时,应加强他克莫司和依维莫司治疗药物监测,并根据谷浓度调整剂量。
- 从泊沙康唑混悬液转换为片剂时,需预期泊沙康唑暴露增加及更显著的药物相互作用,及时下调他克莫司和依维莫司剂量。
局限性
- 单中心研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: A new formulation of posaconazole (PCZ), delayed-release tablets (PCZ-tab), increases PCZ bioavailability and plasma trough concentrations (Cmin ) over those achieved with an oral suspension (PCZ-susp). PCZ is an inhibitor of cytochrome P450 3A4 and P-glycoprotein. We therefore investigated the impact of PCZ-tab treatment on blood Cmin and doses of tacrolimus (TAC) and everolimus (EVR). METHODS: Eighteen lung transplant patients receiving TAC (n = 13) or TAC + EVR (n = 5) between June 2015 and March 2016 were retrospectively included. Ten of these patients received both PCZ-tab and PCZ-susp (i.e. switched patients); the other 8 received only PCZ-tab. Plasma Cmin of PCZ (n = 64), blood Cmin of TAC (n = 299) and EVR (n = 80) were determined during routine therapeutic drug monitoring by liquid chromatography-tandem mass spectrometry. RESULTS: PCZ Cmin on PCZ-tab treatment (n = 48) was 2.5 times higher than that on PCZ-susp therapy (n = 16), for both PCZ patients (P < .0001) and for switched patients (P = .003). PCZ initiation, regardless of galenic form, increased TAC and EVR Cmin adjusted for dose (D), 3-fold and 3.5-fold, respectively (P < .0001 for both). PCZ-tab treatment was associated with a higher TAC Cmin /D (PCZ-tab vs PCZ-susp: 0.004 ± 0.004 L-1 vs 0.009 ± 0.006 L-1 , P < .0001) and lower TAC daily dose than PCZ-susp (PCZ-tab vs PCZ-susp: 1.08 ± 0.92 vs 2.32 ± 1.62 mg d-1 , P < .0001). EVR Cmin /D was higher and EVR dose tended to be lower on PCZ-tab than on PCZ-susp. CONCLUSION: The greater PCZ exposure achieved during PCZ-tab treatment increased drug-drug interactions with TAC and EVR, resulting in greater exposure, potentially exposing patients to higher risks of adverse effects.
引用
- Chanoine S, Gautier-Veyret E, Pluchart H, et al. Tablets or oral suspension for posaconazole in lung transplant recipients? Consequences for trough concentrations of tacrolimus and everolimus. Br J Clin Pharmacol. 2020. PMID: 32472569. doi:10.1111/bcp.14398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。